1. Hu Y, Zhong Q. Basis of estimating pleural effusion size on CT scan: reasonable grouping of volume percentage. Chest. 2013;143:1839.
2. Bosch DJ, Muijs CT, Mul VE, Beukema JC, Hospers GA, Burgerhof JG, et al. Impact of neoadjuvant chemoradiotherapy on postoperative course after curative-intent transthoracic esophagectomy in esophageal cancer patients. Ann Surg Oncol. 2013. doi: 10.1245/s10434-013-3316-8 .
3. Xu CH, Zhan P, Yu LK, Zhang XW. Diagnostic value of pleural interleukin 17 and carcinoembryonic antigen in lung cancer patients with malignant pleural effusions. Tumour Biol J Int Soc Codev Biol Med. 2013. doi: 10.1007/s13277-013-1220-2 .
4. Johnson BE, Kabbinavar F, Fehrenbacher L, Hainsworth J, Kasubhai S, Kressel B, et al. ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31:3926–35.
5. Yang WB, Ye ZJ, Xiang F, Zhang JC, Zhou Q. Th17/Treg imbalance in malignant pleural effusion. Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban. 2013;33:27–32.